Bulent Cetin

Publication Activity (10 Years)

Years Active: 2018-2023
Publications (10 Years): 11

Top Topics

Metastatic Renal Cell Carcinoma

Metastatic Breast Cancer

Ejection Fraction

Endoplasmic Reticulum

Top Venues

Future oncology (London, England)

International urology and nephrology

Current treatment options in oncology

Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer

This page only lists publications with an associated author ORCID identifier.

Publications

Bulent Cetin, Chiara A Wabl, Ozge Gumusay
Should one use the combination of abiraterone and poly(ADP-ribose) polymerase inhibitors as first-line therapy for all patients with metastatic castration-resistant prostate cancer? Future oncology (London, England) (2023)
Bulent Cetin, Chiara A Wabl, Ozge Gumusay
Advancing immunotherapy in gastroesophageal cancer through rational combinations and biomarkers. Immunotherapy (2023)
Bulent Cetin, Chiara A Wabl, Ozge Gumusay
Should one use the combination of abiraterone and poly(ADP-ribose) polymerase inhibitors as first-line therapy for all patients with metastatic castration-resistant prostate cancer? Future oncology (London, England) 18 (39) (2023)
Bulent Cetin, Chiara A Wabl, Ozge Gumusay
Should one use the combination of abiraterone and poly(ADP-ribose) polymerase inhibitors as first-line therapy for all patients with metastatic castration-resistant prostate cancer? Future oncology (London, England) 18 (39) (2023)
Bulent Cetin, Chiara A Wabl, Ozge Gumusay
Should one use the combination of abiraterone and poly(ADP-ribose) polymerase inhibitors as first-line therapy for all patients with metastatic castration-resistant prostate cancer? Future oncology (London, England) 18 (39) (2023)
Gokce Iscan, Bulent Cetin, Faruk Kılıç, Hakan Kalayci, Aysegul Kalayci, Serhan Can Iscan
Investigation of anxiety sensitivity levels of cancer patients in terms of COVID-19 vaccine: a cross-sectional study. Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer 30 (5) (2022)
Bulent Cetin, Chiara A Wabl, Ozge Gumusay
Reshaping Treatment Paradigms for Advanced Renal Cell Cancer Patients and Improving Patient Management : Optimal Management for Renal Cell Cancer Patients. Current treatment options in oncology 23 (4) (2022)
Bulent Cetin, Chiara A Wabl, Ozge Gumusay
CDK4/6 inhibitors: mechanisms of resistance and potential biomarkers of responsiveness in breast cancer. Future oncology (London, England) 18 (9) (2022)
Bulent Cetin, Ozge Gumusay
Understanding relevant immune mechanisms in gastrointestinal oncology. Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners 27 (5) (2021)
Bulent Cetin, Alim Kosar
Game of thrones: immunotherapy versus molecular targeted therapy in renal cell cancer scenarios. International urology and nephrology 51 (12) (2019)
Bulent Cetin, Ipek Isık Gonul, Ozge Gumusay, Irem Bilgetekin, Efnan Algin, Ahmet Ozet, Aytug Uner
Carbonic anhydrase IX is a prognostic biomarker in glioblastoma multiforme. Neuropathology : official journal of the Japanese Society of Neuropathology 38 (5) (2018)